| Status: AWMSG assessment in progress | |
Emicizumab (Hemlibra®) is recommended as an option for use in NHS Wales for the routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype. This recommendation applies only in circumstances where the agreed commercial access arrangement (CAA) between the MA holder and NHS Wales is utilised or where the list / contract price is equivalent or lower than the CAA price. |
|
Medicine details |
|
| Medicine name | emicizumab (Hemlibra®) |
| Formulation | 150 mg/ml solution for subcutaneous injection |
| Reference number | 4742 |
| Indication | For routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype |
| Company | Roche Products Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | Limited |
| Status | AWMSG assessment in progress |
| Scrutiny Panel meeting date | 03/11/2025 |
| LOWMAG meeting date | 15/04/2026 |
| AWMSG meeting date | 20/05/2026 |
| Date of issue | 26/05/2026 |
| Commercial arrangement | CAA |